SEC Company Response from Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — May 14, 2020
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: May 14, 2020 · CIK: 0001262104 · Accession: 0001193125-20-142862
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-238056
Letter
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, CA 92130
May 14, 2020
VIA EDGAR TRANSMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Office of Life Sciences
Re: MEI Pharma, Inc.
Registration Statement on Form S-3
Filed May 7, 2020
File No. 333-238056
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-238056), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on May 18, 2020, or as soon as practicable thereafter.
MEI PHARMA, INC.
By:
/s/ Brian G. Drazba
Name: Brian G. Drazba
Title: Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP MEI Pharma, Inc. 3611 Valley Centre Drive, Suite 500 San Diego, CA 92130 May 14, 2020 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Office of Life Sciences Re: MEI Pharma, Inc. Registration Statement on Form S-3 Filed May 7, 2020 File No. 333-238056 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, MEI Pharma, Inc. (the “Company”), hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-238056), so that such registration statement may become effective at 4:00 p.m. (Washington, D.C. time) on May 18, 2020, or as soon as practicable thereafter. MEI PHARMA, INC. By: /s/ Brian G. Drazba Name: Brian G. Drazba Title: Chief Financial Officer